Monday, January 07, 2013 RedChip Money Report | | | | | | Quick Links: Featured This Week RedChip Initiates Coverage on Neostem, INC. (NYSE MKT: NBS) RedChip Research™, a division of RedChip Companies, Inc., has initiated research coverage on NEOSTEM, INC. (NYSE MKT: NBS), an emerging leader in the fast-growing cell therapy market. According to BCC Research, the global market for stem cell products is expected to grow at nearly 12% annually, from $3.8 billion in 2011 to $6.6 billion in 2016. NeoStem has the expertise and existing research capabilities and collaborators to enable it to achieve its mission of becoming a premier cell therapy company. The Company's service business and pipeline of proprietary cell therapy products work in concert, giving the Company a competitive advantage that is unique in the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a significant intellectual property estate, NeoStem is poised for substantial valuation improvement. | | | RedChip Money Report TV Show RedChip TV This Week: (GD, GLYE, LTBR, XPLR) The eighth episode of "The RedChip Money Report" features interviews with Philip Sassower, CEO of Xplore Technologies Corp. (NASDAQ: XPLR), a leading manufacturer of rugged mobile computing systems; Seth Grae, CEO of Lightbridge Corp. (NASDAQ: LTBR), a provider of next-generation nuclear technology and advisory services; and John Lorenz, CEO of GlyEco, Inc. (OTCQB: GLYE), a green chemistry company with a patent-pending technology for transforming hazardous materials into green products. The episode also features a book review on "Bull!" by Maggie Mahar and a segment on General Dynamics Corp. (NYSE: GD), a market leader in business aviation, land and expeditionary combat systems, armaments and munitions, shipbuilding and marine systems, and information systems and technologies. RedChip Conferences Webcast videos from the REDCHIP SMALL-CAP VIRTUAL CONFERENCE, held on December 5-6, 2012, are now available. The conference featured executive presentations from more than a dozen outstanding growth companies, carefully selected by RedChip. REDCHIP 15TH ANNUAL FALL SMALL-CAP CONFERENCE presentation videos and executive interviews are now available. Over 400 people viewed the live webcast from all over the world, making it one of our most-attended conferences to date. Upcoming Events Conferences: NEOSTEM, INC. (NYSE MKT: NBS) Biotech Showcase™ 2013 Date: January 8, 2013, 4:15 p.m. PST Location: Parc 55 Wyndham, San Francisco, Union Square, San Francisco, CA Scale-Up and Manufacturing of Cell-Based Therapies II Date: January 22, 2013, 4:50 p.m. PST Location: Hyatt Regency Mission Bay Spa and Marina, San Diego, CA Eighth International Conference on Cell Therapy for Cardiovascular Diseases (IC3D 2013) Date: January 24, 2013, 9:30 a.m. EST Location: Vivian and Seymour Milstein Family Heart Center, New York City, NY Phacilitate's Cell & Gene Therapy Forum Date: January 28, 2013 Location: The Grand Hyatt, Washington, DC RedChip Alerts January 2013 Stock Challenge 1. pickeled picke 82.43 % 2. scorpio 26.07 % 3. dapperdan 23.83 % 4. rollice1 20.23 % 5. meme 18.36 % Join the REDCHIP STOCK CHALLENGE, our virtual trading competition. Investors can compete head-to-head against their peers in our monthly contest to win a $50 prepaid gift card. It's Free, it's Easy and it's Fun! To enter, contestants must build a stock portfolio using $10,000 in virtual cash. All stock picks must trade on a U.S. exchange at a minimum stock price of $0.50 and a market capitalization of less than $1 billion at the time of trading. Contestants may execute an unlimited number of stock trades throughout the month. The contestant whose virtual portfolio achieves the largest percentage gain at the end of the one-month period will win a $50 prepaid gift card. Registration is free. Top Small-Cap Stories 1/7/2013 RedChip has exited the China small-cap sector and terminated its contracts with its three Chinese clients. "We made a decision to close our Beijing office months ago and wind down our China operations," stated Dave Gentry, President and CEO... 1/7/2013 In the January 5, 2013 edition of The Wall Street Journal, Gary Becker and Kevin Murphy ask "Have We Lost the War on Drugs?" in a thought-provoking article looking at the issue from many different perspectives. One area in particular weaved... 1/2/2013 South Korea is the world's 11th largest economy, but outdated perceptions held by many investors have the Korean stock market trading at a steep discount to its Asian peers. A major driver of this outdated view is the country's reputation for... 12/21/2012 The 2012 Nobel Prize in Physiology and Medicine was awarded to Shinya Yamanaka of Kyoto University in Japan and John Gurdon of the University of Cambridge in England. Dr. Yamanaka and Dr. Gurdon received the award "for the discovery that mature... 12/20/2012 Mobile app developer MEDL Mobile Holdings, Inc. (OTCBB: MEDL) achieved several major milestones in 2012, as CEO Andrew Maltin discussed during the recent RedChip Small-Cap Virtual Conference. Over the past 12 months, MEDL grew total downloads to... 12/18/2012 Abakan Inc. (OTCQB: ABKI), winner of The Wall Street Journal's 2012 Technology Innovation Award for manufacturing technology, is set to launch its first full-scale pipe cladding facility in Euclid, Ohio. The facility will begin operations in... RedChip Top Performers Ticker Exchange RedChip Engagement Sector Price Appreciation OTC QB September 2012 Industrial Goods +56% NasdaqCM January 2012 Technology +42% *Since March 2009 Biotechnology NEOSTEM, INC. (NYSE MKT: NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization (CDMO), and Hackensack University Medical Center ("HackensackUMC"), part of the Hackensack University Health Network and a hub of healthcare for the Northern New Jersey and New York metropolitan areas, announced that HackensackUMC has renewed its engagement of PCT's services for processing and storage of a variety of cell types used therapeutically by the hospital. | | NBS also announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in January. Technology ASURE SOFTWARE, INC. (NASDAQ: ASUR), a leading provider of workplace management software, announced that they will be presenting at SeeThruEquity's Winter Microcap Investor Conference on Tuesday, January 8, 2013 at The Penn Club in midtown Manhattan. Asure's presentation time is scheduled for 10:15 AM EST. | | IZEA, INC. (OTC QB: IZEA), the pioneer of Social Media Sponsorship, appointed Mitchel J. Laskey to the Company's Board of Directors. Mr. Laskey has been elected to serve as Chairman, replacing Founder and Chief Executive Officer Edward ("Ted") Murphy, who will remain on the Board as a Director and continue serving as Chief Executive of the Company. | | MEDL MOBILE HOLDINGS, INC. (OTC BB: MEDL), a pioneer in the creation, development, marketing and monetization of mobile apps, announced an R-rated update to their hit app, "The Honey Badger Don't Care." | | RedChip Research For nearly two decades, RedChip has published small-cap research focusing on "Discovering Tomorrow's Blue Chips Today." RedChip's long history of success includes being the first to issue independent research coverage on Starbucks in 1992. Often, RedChip follows companies that have no other equity research due to Wall Street's single-minded focus on large-cap corporations and its pursuit of investment banking opportunities. Our analysts rigorously screen small-cap ideas and provide in-depth analysis of the companies that meet our for performance, growth potential and financial fitness. Each company in our is covered in a full analyst report including historical financials, earnings estimates, stock rating, and a 12-month price target. | Recent Reports NBS Initial Report We are initiating coverage of NeoStem, Inc. with a Speculative Buy rating and a 12-month price target of $0.90. We believe NeoStem is currently well positioned to participate in various aspects of cell therapy as it continues to develop and build on its core capabilities, potentially enabling it to produce medically-important cell therapeutics in several chronic diseases. NeoStem's multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary with a medically important cell therapy product development program. | | ASUR 3Q12 Update Asure Software, Inc., a provider of cloud based workplace optimization software, continued to report strong YoY growth in 3Q12. Revenue of $5.7 million represented an increase of 126% YoY, driven primarily by the acquisitions of PeopleCube, ADI Time and Legiant and the 22% YoY increase in cloud bookings. Recurring revenue accounted for 80% of revenue in 3Q12, up from 76% of revenue in 1Q12 & 2Q12. We expect this total to increase in coming quarters as ASUR completes its shift toward becoming a completely SaaS-based provider. Total deferred revenue of $9.7 million as of 9/30/12 represented a 263% increase compared to total deferred revenue of $2.7 million as of 9/30/11. The Company reported free cash flow (FCF) of $463K, which was in line with our estimate of $479K. We expect FCF to become more robust beginning in 4Q12 due to the completion of one-time costs related to the PeopleCube acquisition, increased bookings as the Company fully digests the PeopleCube acquisition, and a more robust service offering to its clients following the PeopleCube acquisition and FotoPunch partnership. | | MXOM Initial Report Pan American Goldfields Ltd. is a junior producer/explorer with two main assets: the Cieneguita Mine in Mexico and the greenfield Cerro Delta project in Argentina. The Company currently receives 29% of the net profits from the Cieneguita mine; however, from Jan-Dec 2013, MXOM will begin to receive 35% of the net profits from the Cieneguita mine, which is currently producing about 550 tpd at grades of approximately 1.4 g/t Au and 85 g/t Ag. Additionally, a Preliminary Economic Assessment is expected to be completed on the Cieneguita Mine in late 4Q12; this is expected to explore the possibility of a 100,000 Au Equivalent ounce per year operation. We believe that the PEA, plus the increase in net cash flow from the Cieneguita Mine beginning in 2013, represent two near-term catalysts for MXOM. | | Additional Analyst Reports UNRH 2Q12 Update MEDL Initial Report CDXC 2Q12 Update APNT 2Q12 Update ASUR 2Q12 Update About RedChip RedChip Companies, Inc. is a well-established source of independent research and information on the small-cap markets. Dedicated to "Discovering Tomorrow's Blue Chips Today™," our analysts seek out emerging growth companies and undiscovered small-cap values before they show up on Wall Street's radar screen. RedChip analysts provide a unique breadth of coverage and depth of research on undiscovered small-cap companies. | | | © RedChip Companies, Inc. | 500 Winderley Place, Ste. 100 | Maitland, FL 32751 To unsubscribe, simply and enter the email address which received this message.
